<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339166</url>
  </required_header>
  <id_info>
    <org_study_id>ESNi-PGT</org_study_id>
    <nct_id>NCT04339166</nct_id>
  </id_info>
  <brief_title>Embryo Selection by Noninvasive Preimplantation Genetic Test</brief_title>
  <acronym>ESNi-PGT</acronym>
  <official_title>A Multicenter Clinical Study on Embryo Selection by Using the Ploidy of Cell Free DNA in Embryo Culture Medium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinling Hospital,Nanjing University,School Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Maternity and Reproductive hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwest Women's and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Medical Center of Chinese People's Liberation Army General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yikon Genomics Company, Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to explore whether non-invasive chromosome screening (NICS)
      can be used as an effective indicator for embryos selection besides morphology through a
      multicenter randomized controlled trial, by comparing the differences of live birth rate,
      pregnancy rate and miscarriage rate between the two groups of embryo selection by &quot;NICS+
      morphology&quot; and embryo selection only by &quot;morphology&quot; in IVF cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chromosomal abnormalities commonly exist in early human embryos, and often cause embryo
      implantation failure and pregnancy loss in in-vitro fertilization (IVF) treatments.
      Preimplantation genetic testing for aneuploidies (PGT-A) by comprehensive chromosome
      screening (CCS) has been widely applied in IVF practices to select embryos with normal
      ploidy. Although multiple clinical trials have demonstrated improved clinical outcomes with
      PGT-A, it's in controversial for whether PGT-A is truly worthwhile to be offered to all IVF
      patients. One of the main concerns is that it involves an embryo biopsy procedure, which is
      invasive and the long-term safety issue of the embryo biopsy remains to be fully
      investigated.

      In recent years, researchers have found that the spent medium of embryo culture contains
      trace amount of cell-free DNA, which may reflect the ploidy of the embryo. The non-invasive
      chromosome screening (NICS) approach utilizing spent culture medium samples has been
      evaluated in studies. However, the clinical value of NICS as a new effective indicator to
      evaluate embryo competence so far has not been justified by randomized clinical trials.

      The main purpose of this project is to verify whether NICS can be used as a new effective
      indicator for evaluating embryo developmental potential through multi-center, randomized
      clinical trials
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks after the first embryo transfer</time_frame>
    <description>Number of women with ongoing pregnancies after the first transfer/ number of women randomized to the specific group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>7 weeks after the first embryo transfer</time_frame>
    <description>Number of women with clinical pregnancies after the first transfer / number of women randomized to the specific group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>28 weeks of after the first embryo transfer</time_frame>
    <description>Number of pregnancy losses / number of clinical pregnancies after the first transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>within 2 weeks after live birth</time_frame>
    <description>Number of women with live births after the first transfer / number of women randomized to the specific group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1148</enrollment>
  <condition>Infertility</condition>
  <condition>Chromosome Abnormality</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Single thawed blastocyst transfer with blastocyst selection according to morphologic score.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-invasive chromosome screening（NICS）</intervention_name>
    <description>NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infertile couples receiving IVF- ICSI procedure for assisted reproduction cycle

          2. Female age: 35 - 42 years old

          3. Women receiving controlled ovarian hyperstimulation treatment (including ultra-long
             protocol、long-protocol 、short protocol treatment with GnRH agonist and GnRH antagonist
             treatment protocol); and the number of oocytes ≥6; The female BMI is from 18 to
             30kg/m2.

          4. Culture embryos to blastocyst stage and all the blastocysts will be single
             cryopreserved.

          5. Single frozen-thawed blastocyst Transferred for the first time

          6. The number of blastocysts ≥2, morphology grade (above 4BC/4CB)

          7. Written informed consent

        Exclusion Criteria:

          1. One of couples with IVF or ICSI contraindications(such as poorly controlled type I or
             type II diabetes; liver disease or dysfunction; kidney disease or renal function
             abnormality; significant anemia; history of deep venous thrombosis, pulmonary embolus;
             history of cerebrovascular accident; uncontrolled hypertension or diagnosed heart
             disease; history of cervical, endometrial or breast cancer; undiagnosed vaginal
             bleeding.)

          2. PGT cycles

          3. Women who have pathologies or malformations that affect the pregnancy outcome: genital
             malformations, untreated hydrosalpinx, untreated uterine infections, intramural myomas
             &gt; 4cm , benign tumor of pelvic and abdominal cavity&gt; 4cm, intimal thickness＜8mm,
             pituitary tumors and malignant tumors of various tissues and organs during the
             patient's participation in the study

          4. Untreated hyperprolactinemia, thyroid disease, adrenal disease

          5. Women with endometrial polyps that were not treated before embryo transfer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>IVF patients</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Qiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Qiao</last_name>
    <phone>010-82265080</phone>
    <email>jie.qiao@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>yanwen xu, professor</last_name>
      <phone>020-87606345</phone>
      <email>xuyanwen@live.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei Maternity and Reproductive hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liyi Cai</last_name>
      <phone>0311-82626066</phone>
      <email>cai760829@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of Citic-Xiangya</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liang Hu</last_name>
      <phone>0731-82355100-8973</phone>
      <email>lianghu7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinling Hospital,Nanjing University,School Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bing Yao</last_name>
      <phone>025-80860174</phone>
      <email>yaobing@nju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiuxia Wang</last_name>
      <phone>024-9661540131</phone>
      <email>wangxxsj@sina.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Qiao</last_name>
      <phone>010-82265080</phone>
      <email>jie.qiao@263.net</email>
    </contact>
    <investigator>
      <last_name>Jie Qiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Medical Center of Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuanqing Yao</last_name>
      <phone>010-66939258</phone>
      <email>yqyao@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest women's and children's hospital</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Juanzi Shi</last_name>
      <phone>029-87219120</phone>
      <email>shijuanzi123@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Jie Qiao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Culture media</keyword>
  <keyword>Embryonic cell-free DNA</keyword>
  <keyword>Euploidy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

